Immunic to Engage in Key Scientific Conferences in April

Immunic, Inc., a biotechnology firm listed on Nasdaq under the symbol IMUX, has announced its participation in two significant scientific and medical events in April. The company is advancing in the field of oral therapies for neurologic diseases. At the 8th Annual Neuroimmunology Drug Development Summit in Boston, from April 14-16, Chief Scientific Officer Hella Kohlhof will present their lead asset, vidofludimus calcium (IMU-838). This asset targets multiple sclerosis and exhibits both neuroprotective and anti-inflammatory properties. Details of the presentation will be accessible on Immunic's website.

Further, the firm will attend the 2026 American Academy of Neurology Annual Meeting from April 18-22 in Chicago with its management and medical teams. This provides an opportunity for conference attendees to engage directly with Immunic's representatives. Vidofludimus calcium, currently in phase 3 trials, has shown promise in treating relapsing multiple sclerosis. Immunic's pipeline also includes other promising therapies aimed at addressing broader neurologic conditions.